Semaglutide as a GLP1 Receptor Agonist : This medication mimics the naturally occurring GLP-1 hormone to improve glycemic control and effectively manage weight loss
14,15,16 Mendelian randomization studies have demonstrated no causal relationship between elevated uric acid levels and the risks of diabetes, coronary heart disease, ischemic stroke, heart failure, body mass index, bone mineral density, coronary artery disease, blood pressure, metabolic syndrome, blood glucose levels, triglyceride levels, diabetes mellitus, serum creatinine levels, glomerular filtration rate, and Parkinsons disease
Running two agonists on the same receptor doesn't double the signal it creates receptor competition and compounding side effect risk without proportional benefit
What's the argument against going on to one of these online sites